Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Spyre Therapeutics Announces Grants of Inducement Awards
SYRE Stock Jumps More Than 70% in a Month: What Is Driving This Rally?
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up Following Analyst Upgrade
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
Spyre Therapeutics: Strong SPY001 Data Set Up A Catalyst-Rich 2026
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Transcript
Spyre Therapeutics Breaks Higher On Positive Data From Ulcerative Colitis Drug
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026
Spyre CEO Sells $740K in Stock After 300% Surge as Key Q3 Data Nears
Spyre Therapeutics (NASDAQ:SYRE) CEO Cameron Turtle Sells 15,000 Shares
Scott Burrows Sells 7,500 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock
Spyre Therapeutics Announces Grants of Inducement Awards
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools
Spyre: 'Strong Buy' As UC Program Moves Along And Q3 2026 RA Data Looms
Spyre Therapeutics, Inc. $SYRE Shares Bought by B Group Inc.
Spyre Therapeutics, Inc. (SYRE) Presents at Leerink Global Healthcare Conference 2026 Transcript
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Spyre Therapeutics Announces Grants of Inducement Awards
Short Interest in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Drops By 13.5%
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of “Buy” by Brokerages
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
Spyre Therapeutics' CEO Sells 15,000 Shares
Spyre Therapeutics Announces Grants of Inducement Awards
Cameron Turtle Sells 15,000 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock
Spyre Therapeutics: Validated Targets, Optimized Delivery
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics, Inc. $SYRE Shares Purchased by Intech Investment Management LLC
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
Intelligent Development Could Make Spyre Therapeutics Best In Show
Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward
Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts